Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2019 Feb 15;25(4):1435. doi: 10.1158/1078-0432.CCR-18-4266. No abstract available.

PMID:
30770494
2.

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2019 Feb 12. doi: 10.1038/s41586-019-0974-0. [Epub ahead of print]

PMID:
30755741
3.

Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT.

Ulaner GA, Bodei L.

Clin Nucl Med. 2019 Jan 25. doi: 10.1097/RLU.0000000000002467. [Epub ahead of print]

PMID:
30688738
4.

ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast.

Expert Panel on Breast Imaging:, Niell BL, Lourenco AP, Moy L, Baron P, Didwania AD, diFlorio-Alexander RM, Heller SL, Holbrook AI, Le-Petross HT, Lewin AA, Mehta TS, Slanetz PJ, Stuckey AR, Tuscano DS, Ulaner GA, Vincoff NS, Weinstein SP, Newell MS.

J Am Coll Radiol. 2018 Nov;15(11S):S313-S320. doi: 10.1016/j.jacr.2018.09.017.

PMID:
30392600
5.

Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases.

Kurilova I, Beets-Tan RGH, Flynn J, Gönen M, Ulaner G, Petre EN, Edward Boas F, Ziv E, Yarmohammadi H, Klompenhouwer EG, Cercek A, Kemeny NA, Sofocleous CT.

Clin Colorectal Cancer. 2018 Sep 13. pii: S1533-0028(18)30250-0. doi: 10.1016/j.clcc.2018.08.004. [Epub ahead of print]

PMID:
30297264
6.

Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists.

Huicochea Castellanos S, Corrias G, Ulaner GA, Dunphy M, Junting Z, Capanu M, Balachandran V, Giancipoli RG, Monti S, Mannelli L.

Abdom Radiol (NY). 2018 Sep 24. doi: 10.1007/s00261-018-1765-z. [Epub ahead of print]

PMID:
30251132
7.

18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men.

Ulaner GA, Juarez J, Riedl C, Goldman D.

J Nucl Med. 2018 Sep 20. pii: jnumed.118.217836. doi: 10.2967/jnumed.118.217836. [Epub ahead of print]

PMID:
30237211
8.

Uses and Opportunities for Molecular Imaging in Patients with Breast Cancer.

McDonald ES, Ulaner GA.

PET Clin. 2018 Jul;13(3):xi-xii. doi: 10.1016/j.cpet.2018.05.001. No abstract available.

PMID:
30100083
9.

Amino Acid Metabolism as a Target for Breast Cancer Imaging.

Ulaner GA, Schuster DM.

PET Clin. 2018 Jul;13(3):437-444. doi: 10.1016/j.cpet.2018.02.009. Review.

PMID:
30100081
10.

Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.

Henry KE, Ulaner GA, Lewis JS.

PET Clin. 2018 Jul;13(3):423-435. doi: 10.1016/j.cpet.2018.02.010. Review.

PMID:
30100080
11.

Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application.

Chakraborty D, Basu S, Ulaner GA, Alavi A, Kumar R.

PET Clin. 2018 Jul;13(3):355-361. doi: 10.1016/j.cpet.2018.02.011. Review.

PMID:
30100075
12.

Molecular Classification of Breast Cancer.

Provenzano E, Ulaner GA, Chin SF.

PET Clin. 2018 Jul;13(3):325-338. doi: 10.1016/j.cpet.2018.02.004. Epub 2018 May 7. Review.

PMID:
30100073
13.

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG.

J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):362.

14.

Mazabraud's Syndrome Mimicking Metastases on FDG PET/CT in a Patient With Colon Cancer.

Mahajan S, Goel R, Riedl C, Ulaner GA.

Clin Nucl Med. 2018 Aug;43(8):625-626. doi: 10.1097/RLU.0000000000002151.

PMID:
29863575
15.

Trends in oncologic hybrid imaging.

Wibmer AG, Hricak H, Ulaner GA, Weber W.

Eur J Hybrid Imaging. 2018;2(1):1. doi: 10.1186/s41824-017-0019-6. Epub 2018 Jan 19. Review.

16.

90Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material.

Kurilova I, Beets-Tan RGH, Ulaner GA, Boas FE, Petre EN, Yarmohammadi H, Ziv E, Deipolyi AR, Brody LA, Gonen M, Sofocleous CT.

Cardiovasc Intervent Radiol. 2018 Sep;41(9):1419-1427. doi: 10.1007/s00270-018-1985-1. Epub 2018 May 15.

PMID:
29766239
17.

Adalimumab-Induced Epstein-Barr Virus-Related Lymphoproliferative Disorder on FDG PET/CT.

Ward J, Noy A, Ulaner G, Riedl C.

Clin Nucl Med. 2018 May;43(5):344-345. doi: 10.1097/RLU.0000000000002054.

PMID:
29538028
18.

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL.

Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22. No abstract available.

19.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31. Erratum in: Nature. 2019 Feb 12;:.

20.

Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management.

Sawan P, Rebeiz K, Schoder H, Batlevi C, Moskowitz A, Ulaner GA, Dunphy M, Mannelli L.

Medicine (Baltimore). 2017 Dec;96(51):e9411. doi: 10.1097/MD.0000000000009411.

21.

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM.

JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029.

22.

First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.

Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O'Donoghue JA.

J Nucl Med. 2018 Jun;59(6):900-906. doi: 10.2967/jnumed.117.202010. Epub 2017 Nov 16.

23.

89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA.

Clin Nucl Med. 2017 Dec;42(12):912-917. doi: 10.1097/RLU.0000000000001820.

24.

Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer.

Cornelis FH, Durack JC, Pandit-Taskar N, Ulaner GA, Lewis JS, Morris MJ, Solomon SB.

J Nucl Med. 2018 Mar;59(3):399-402. doi: 10.2967/jnumed.117.194480. Epub 2017 Aug 17.

25.

David Versus the Goliaths for the Detection of Bone Metastases.

Ulaner GA.

J Nucl Med. 2017 Nov;58(11):1776-1777. doi: 10.2967/jnumed.117.199893. Epub 2017 Aug 17. No abstract available.

26.

High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.

Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J.

Blood. 2017 Aug 24;130(8):1007-1013. doi: 10.1182/blood-2017-01-761718. Epub 2017 Jul 5.

28.

Pathologically Benign Lymph Nodes Can Mimic Malignancy on Imaging in Patients With Angiomatoid Fibrous Histiocytoma.

Ulaner GA, Healey JH, Athanasian EA.

Clin Orthop Relat Res. 2017 Sep;475(9):2274-2279. doi: 10.1007/s11999-017-5388-4. Epub 2017 May 23.

29.

Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.

Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS, McArthur HL, Gönen M, Dickler M, Weber WA.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1428-1437. doi: 10.1007/s00259-017-3703-7. Epub 2017 May 1.

30.

18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer.

Ulaner GA, Castillo R, Wills J, Gönen M, Goldman DA.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1420-1427. doi: 10.1007/s00259-017-3709-1. Epub 2017 Apr 29.

PMID:
28456837
31.

Value of second-opinion review of outside institution PET-CT examinations.

Ulaner GA, Mannelli L, Dunphy M.

Nucl Med Commun. 2017 Apr;38(4):306-311. doi: 10.1097/MNM.0000000000000647.

32.

Transient Osteoporosis of the Hip on FDG PET/CT.

Ulaner GA, Sawan P.

Clin Nucl Med. 2017 May;42(5):401-402. doi: 10.1097/RLU.0000000000001630.

33.

FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer.

Ulaner GA, Zindman AM, Zheng J, Kim TW, Healey JH.

Clin Nucl Med. 2017 Apr;42(4):264-270. doi: 10.1097/RLU.0000000000001580.

34.

"Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply.

Young RJ, Yang TJ, Hatzoglou V, Ulaner G, Omuro A.

Neuro Oncol. 2017 Feb 1;19(2):301-302. doi: 10.1093/neuonc/now286. No abstract available.

35.

18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2017 Jun 15;23(12):3053-3060. doi: 10.1158/1078-0432.CCR-16-2197. Epub 2016 Dec 23. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1435.

36.

Prospective Clinical Trial of 18F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers.

Ulaner GA, Goldman DA, Corben A, Lyashchenko SK, Gönen M, Lewis JS, Dickler M.

J Nucl Med. 2017 Jul;58(7):1037-1042. doi: 10.2967/jnumed.116.183335. Epub 2016 Nov 17.

37.

FDG-Avid Intrathecal Inflammation Following Administration of Intrathecal Methotrexate.

Hogan MP, Osborne J, Ulaner GA.

Clin Nucl Med. 2016 Dec;41(12):995-997.

38.

Unilateral Suppression of Brown Fat on FDG PET/CT in Horner Syndrome.

Ulaner GA, Samstein R, Cahlon O, Weber WA, Rimner A.

Clin Nucl Med. 2016 Oct;41(10):797-8. doi: 10.1097/RLU.0000000000001319.

PMID:
27454597
39.

Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients.

Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL, Gonen M, Jochelson M, Weber WA.

Am J Nucl Med Mol Imaging. 2016 Apr 24;6(2):120-7. eCollection 2016.

40.

Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.

Shady W, Kishore S, Gavane S, Do RK, Osborne JR, Ulaner GA, Gonen M, Ziv E, Boas FE, Sofocleous CT.

Eur J Radiol. 2016 Jun;85(6):1224-31. doi: 10.1016/j.ejrad.2016.03.029. Epub 2016 Mar 31.

41.

Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT.

Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, McArthur H, Erinjeri JP, Solomon SB, Kolb H, Lyashchenko SK, Lewis JS, Carrasquillo JA.

J Nucl Med. 2016 Oct;57(10):1523-1528. Epub 2016 May 5.

42.

(18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.

Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, Jochelson MS, Gönen M.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1937-44. doi: 10.1007/s00259-016-3402-9. Epub 2016 Apr 30.

43.

The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST.

Pinker K, Riedl CC, Ong L, Jochelson M, Ulaner GA, McArthur H, Dickler M, Gönen M, Weber WA.

J Nucl Med. 2016 Jul;57(7):1102-4. doi: 10.2967/jnumed.115.166629. Epub 2016 Mar 16.

44.

Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.

Ulaner GA, Goldman DA, Gönen M, Pham H, Castillo R, Lyashchenko SK, Lewis JS, Dang C.

J Nucl Med. 2016 Sep;57(9):1350-6. doi: 10.2967/jnumed.115.170456. Epub 2016 Mar 3.

45.

Molecular Imaging of Biomarkers in Breast Cancer.

Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N, Weber W.

J Nucl Med. 2016 Feb;57 Suppl 1:53S-9S. doi: 10.2967/jnumed.115.157909. Review.

46.

A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation.

Hatzoglou V, Yang TJ, Omuro A, Gavrilovic I, Ulaner G, Rubel J, Schneider T, Woo KM, Zhang Z, Peck KK, Beal K, Young RJ.

Neuro Oncol. 2016 Jun;18(6):873-80. doi: 10.1093/neuonc/nov301. Epub 2015 Dec 19.

47.

Detection of Internal Mammary Adenopathy in Patients With Breast Cancer by PET/CT and MRI.

Jochelson MS, Lebron L, Jacobs SS, Zheng J, Moskowitz CS, Powell SN, Sacchini V, Ulaner GA, Morris EA, Dershaw DD.

AJR Am J Roentgenol. 2015 Oct;205(4):899-904. doi: 10.2214/AJR.14.13804.

48.

Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.

Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, Jochelson M, Hudis C, Morrow M, Ulaner GA.

J Nucl Med. 2015 Nov;56(11):1674-80. doi: 10.2967/jnumed.115.161455. Epub 2015 Aug 20.

50.

Reply: Breast Cancer Staging: To Which Women Should 18F-FDG PET/CT Be Offered?

Ulaner GA, Riedl CC.

J Nucl Med. 2015 Aug;56(8):1293-4. doi: 10.2967/jnumed.115.161042. Epub 2015 Jun 25. No abstract available.

Supplemental Content

Loading ...
Support Center